AGL

agilon health, inc. (AGL) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-08-01

Overall Score

Growth

Revenue growth is not enough to offset weak profitability, with TTM net margin at -4.24% and operating margin at -4.48%.

Asset turnover is high at 3.72x, but the business is still generating negative operating cash flow and negative free cash flow.

Profitability

TTM return on equity is -119.3% and return on invested capital is -90.2%, indicating severe value destruction.

Gross margin is effectively flat at 0.00%, while EBIT margin remains negative at -4.43%.

Financial Health

Liquidity is acceptable with a current ratio of 1.08x and quick ratio of 1.08x.

Leverage is modest with debt-to-equity at 0.15x and net debt to EBITDA at 0.32x, but solvency remains weak given negative earnings and cash flow.

Valuation

The stock screens cheap on sales at 0.25x EV/sales, but negative EBITDA and free cash flow make earnings-based valuation metrics unreliable.

Price-to-book is 6.50x, which is not compelling given the company’s negative returns on capital.

Momentum

No positive momentum signal is evident from the latest fundamentals, as profitability and cash generation remain negative.

The market is valuing the company at a low sales multiple, but that appears driven by weak operating performance rather than improving fundamentals.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on agilon health, inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →